Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.

Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. .

Menu

Articles

Read articles and interviews on investing in startups, venture capital funds, tax saving and retirement planning strategies and the latest industry trends, from diversity to cleantech and sustainability. You''ll also find interviews and podcasts with our founders and angel investors.

Access EIS investments for April 2025

Access EIS investments for April 2025

Read about the companies the Access EIS Fund invested in in April 2025

SyndicateRoom's Carbon13 SEIS 7 Fund now fully subscribed

SyndicateRoom's Carbon13 SEIS 7 Fund now fully subscribed

Syndicate Room and Carbon13 close first joint SEIS fund - proving appetite for climatetech amongst UK's angel community continues in 2025. Read the full press release here.

Company spotlight: OSSTEC

Company spotlight: OSSTEC

Next gen orthopaedic implant innovator OSSTEC has seen its share price triple since the Access EIS Fund invested in March 2023. We spoke to CEO and Founder, Maxwell Munford, about the development and growth of a groundbreaking medtech company and what lies ahead.

Access EIS investments for March 2025

Access EIS investments for March 2025

In March we invested in healthtech company Mindspire, which provides a range of services to help users reduce stress using a range of data science techniques.

Deep Blue Biotech is producing carbon-negative chemicals using bacteria

Deep Blue Biotech is producing carbon-negative chemicals using bacteria

Carbon13 portfolio company Deep Blue Biotech's revolutionary technology is making waves with an innovative approach to chemical production. Find out more and listen to the podcast.

Access EIS portfolio company Osstec’s share price triples

Access EIS portfolio company Osstec’s share price triples

OSSTeC share value triples in Access EIS portfolio. Learn how this innovative medical technology company delivered strong returns and find similar investment opportunities.

The UK's fastest growing drinks-brand, MOTH Drinks, on turning an idea into a success

How did a single litre of Chai Masala Old Fashioned turn into a global premium ready-to-drink brand? MOTH is the UK's fastest growing premium ready-to-drink brand, with a 41% share of the UK's premium RTD category. Find out more about the business, how it got started and how it found success.

Three exciting new additions to the Access EIS portfolio for February 2025

Three exciting new additions to the Access EIS portfolio for February 2025

Read about the innovative new startups Access EIS and its network of angels backed in February 2025.

Definitive climate technologies for 2025 and more, an interview with Carbon13's Sara Jones

Definitive climate technologies for 2025 and more, an interview with Carbon13's Sara Jones

Find out what lies ahead in climatetech, what are the sectors and technologies to watch, and what sets Carbon13 portfolio companies apart.

Load more articles

Showing 9 of 118 articles

Risk warning: Please click here to read the full risk warning.

Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.

This page has been approved as a financial promotion by Syndicate Room Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 613021).

We use cookies to improve our service. By continuing to use this site you are agreeing to their use. Find out more. .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndicate Room Ltd is registered in England and Wales. Number 07697935. Registered office: Wellington House, East Road, Cambridge, Cambridgeshire, CB1 1BH, United Kingdom

General enquiries

Please note: our office hours are weekdays, 9.30am - 5.30pm.

Email:

contactus@syndicateroom.com

Phone:

Existing investors

Email:

investor.relations@syndicateroom.com

Phone: